Share the post "Delivery Share breakouts today insights on 04-Sep-2024"
Company Name | Initial Breakout Date | Initial Delivery Value | Final Breakout Date | Final Delivery Value | Delivery (In %) | Breakout | Current Price | High Price(52 W) | Low price (52 W) | Marketcap |
---|---|---|---|---|---|---|---|---|---|---|
India Lease Devl | Aug 30, 2024 | 10,418.73K | 04-Sep-2024 | 14,902.07K | 74.98% | 5 Years | Rs16.06 | Rs16.06 | Rs5.21 | 23.61 Cr |
Pfizer | Jul 15, 2024 | 998,058.90K | 04-Sep-2024 | 1,338,451.32K | 88.28% | 3 Years | Rs6154.45 | Rs6452.85 | Rs3804.15 | 28,155.21 Cr |
India Lease Devl demonstrated diverse delivery trends during the 5 Years breakout period. Starting at 10,418.73K units on Aug 30, 2024, the delivery volume escalated to 14,902.07K units by 04-Sep-2024, marking a delivery rate of 74.98%. Throughout this breakout, the stock’s price fluctuated between a low of Rs15.01 and a high of Rs16.06, with the current price resting at Rs16.06. The company’s market capitalization is currently valued at 23.61 crores.
Pfizer demonstrated diverse delivery trends during the 3 Years breakout period. Starting at 998,058.90K units on Jul 15, 2024, the delivery volume escalated to 1,338,451.32K units by 04-Sep-2024, marking a delivery rate of 88.28%. Throughout this breakout, the stock’s price fluctuated between a low of Rs6045.45 and a high of Rs6194.95, with the current price resting at Rs6154.45. The company’s market capitalization is currently valued at 28,155.21 crores.
India Lease Devl. Ltd.,
0.00
Net Sales
-2.43
Net Profit
1.67
Total Income
-1.81
Expenditure
9.06
Current Price
13.3
Market Cap
The financial snapshot for India Lease Devl. Ltd., reveals a noteworthy performance this quarter. Net sales amounted to ₹0.00 million and total income was ₹1.67 million. The company's expenditure was ₹-1.81 million, leading to a net profit of ₹-2.43 million. Earnings per Share (EPS) for continuing operations were ₹0.00. The report also highlights other income of ₹1.67 million, finance costs of ₹0.00 million, and employee benefit expenses of ₹-1.06 million. Depreciation and amortization costs were ₹-0.01 million, while current and deferred taxes were ₹-2.29 million and ₹0.00 million, respectively. The total comprehensive income for the period stood at ₹0.00 million, with other comprehensive income net of taxes at ₹0.00 million.
The company has a market capitalization of ₹13.3 crore and a current stock price of ₹9.06. Historically, the stock has fluctuated between ₹14.3 / 5.21. With a Price-to-Earnings (P/E) ratio of , the stock appears highly valued. The book value per share is ₹7.51, and the dividend yield is 0.00%. The Return on Capital Employed (ROCE) is -1.26% and the Return on Equity (ROE) is -1.35%. The debt-to-equity ratio is very low at 0.00, although the company reports a net cash flow of ₹-0.07 crore. The Piotroski score is 2.00, and the Graham Number estimates the intrinsic value of the stock at ₹. The Price-to-Book (P/B) ratio is 1.21, indicating the stock is trading at a premium relative to its book value.
Pfizer Limited
5,628.60
Net Sales
1,507.10
Net Profit
6,047.00
Total Income
4,020.80
Expenditure
6,094
Current Price
27,877
Market Cap
In the most recent financial analysis for Pfizer Limited, key metrics demonstrate a solid performance. The net sales reached ₹5,628.60 million, with total income amounting to ₹6,047.00 million. Expenditure was recorded at ₹4,020.80 million, resulting in a net profit of ₹1,507.10 million. EPS figures for continuing operations are ₹32.94. Other notable figures include other income of ₹418.40 million, finance costs of ₹21.10 million, and employee benefit expenses totaling ₹913.70 million. Depreciation and amortization expenses were ₹146.00 million, with current tax at ₹550.50 million and deferred tax at ₹-31.40 million. The total comprehensive income for the period was ₹1,501.70 million, and other comprehensive income net of taxes was ₹-5.40 million.
The company has a market capitalization of ₹27,877 crore and a current stock price of ₹6,094. Historically, the stock has fluctuated between ₹6,453 / 3,802. With a Price-to-Earnings (P/E) ratio of 182, the stock appears highly valued. The book value per share is ₹302, and the dividend yield is 0.57%. The Return on Capital Employed (ROCE) is 27.2% and the Return on Equity (ROE) is 19.8%. The debt-to-equity ratio is very low at 0.00, although the company reports a net cash flow of ₹63.7 crore. The Piotroski score is 8.00, and the Graham Number estimates the intrinsic value of the stock at ₹826. The Price-to-Book (P/B) ratio is 20.2, indicating the stock is trading at a premium relative to its book value.